BioMarin Pharma (BMRN) Misses Q4 EPS by 7c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $64.63 -2.86%
EPS Growth %: +1,016.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +1,016.7%
Financial Fact:
Royalty and license revenues: 1.63M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $358.3 million versus the consensus estimate of $351.62 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.48 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Chime to acquire Stride Bank for $590M in cash
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
